VACC
Get informed when a big investor buys or sells
+ Follow| Market cap | $192.73 Million |
|---|---|
| Enterprise Value | $144.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.64 |
| Beta | -0.27 |
| Outstanding Shares | 40,848,893 |
| P/E Ratio | -0.6 |
|---|---|
| PEG | 1.21 |
| Price to Sales | - |
| Price to Book Ratio | 5.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -24.39 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.19 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platf...